Between 2003 and 2007 , 1071 men with locally advanced prostate cancer were randomly allocated , using a 2 2 trial design , to 6 months i.m. leuprorelin ( androgen suppression [ AS ] ) before radiotherapy alone 12 months additional leuprorelin 18 months zoledronic acid ( ZdA ) , commencing at randomization .